AccurKardia, Wellysis Sign Deal to Provide Cardiac Monitoring in the U.S. 

July 9, 2026 — AccurKardia, Inc. and Wellysis have  announced a multi-year agreement under which AccurKardia’s AccurECG 2.0 will power the analytics behind Wellysis’ turnkey cardiac monitoring offering in the U.S.  

Under the agreement, Wellysis’ S-Patch wearable device will be paired with AccurKardia’s automated ECG analytics and reporting platform to deliver a complete, clinician-ready solution for Holter, extended Holter, and mobile cardiac telemetry workflows. All data is analyzed by AccurECG 2.0, AccurKardia’s FDA-cleared Class II software as a medical device, and delivered in a report ready for physician review. The combined offering gives U.S. cardiology and general medicine practices access to a seamless, end-to-end monitoring solution that integrates hardware, analytics and reporting into a single workflow delivering patient reports faster to improve outcomes. The agreement between AccurKardia and Wellysis follows the integration of the companies’ platforms in April 2025, with AccurKardia becoming an approved vendor to Wellysis in June 2025.

'Comitted to Improving Cardiac Care'

“This partnership demonstrates the power of close collaboration between two teams committed to improving cardiac care,” said Juan C. Jimenez, co-founder and CEO of AccurKardia. “We are excited to serve as the analytics engine powering Wellysis’ offering in the U.S. By combining the S-Patch with our automated, FDA-cleared ECG analytics platform, we are giving clinicians a complete, ready-to-use monitoring solution that fits directly into their workflow. It is a strong validation of our platform and the value we can deliver to partners bringing high-quality cardiac monitoring to market at scale.”

“From the beginning, our goal at Wellysis has been to make high-quality, accessible ECG monitoring a reality for clinicians and patients everywhere,” said Young Juhn, chief executive officer of Wellysis. “Bringing our S-Patch together with AccurKardia’s automated analytics and reporting platform allows us to offer a truly turnkey solution to the U.S. market. AccurKardia has been a solid partner throughout our collaboration, and we are excited to build on that foundation as we expand together in the United States.”